Vanguard Global Advisers
PLRX icon

Vanguard Global Advisers’s Pliant Therapeutics PLRX Stock Holding History

Vanguard Global Advisers’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.1K Hold
19,507
– – ﹤0.01% 3341
2026
Q2 		$22.2K Hold
19,507
– – ﹤0.01% 3303
2026
Q1 		$24.6K Buy
+19,507
New +$24.6K ﹤0.01% 3250

Other funds holding PLRX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Global Advisers's PLRX Position: Q3 2026 in Review

Vanguard Global Advisers held its Pliant Therapeutics (PLRX) position steady in Q3 2026 at 19,507 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3341.

Vanguard Global Advisers first reported a position in PLRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $24.6K in Q1 2026. 49 funds tracked by Wall St. Rank hold PLRX as of Q3 2026.

  • Vanguard Global Advisers held 19,507 shares of Pliant Therapeutics worth $21.1K as of Q3 2026.
  • Vanguard Global Advisers left its Pliant Therapeutics share count unchanged in Q3 2026.
  • Pliant Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3341 holding.
  • Vanguard Global Advisers first reported a position in Pliant Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Pliant Therapeutics position peaked at $24.6K in Q1 2026.
  • 49 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.